Cerebral amyloid angiopathy is a condition in which a sticky protein called amyloid beta accumulates in the walls of blood vessels in the brain, gradually weakening them and raising the risk of bleeding, cognitive decline, and dementia. It is overwhelmingly a disease of aging: mild deposits can be found at autopsy in a large share of elderly brains, but clinically significant cases, the ones that cause symptoms, tend to appear after age 60 and become more common with each decade. Because CAA shares a culprit protein with Alzheimer’s disease yet damages the brain through different routes, it occupies an unusual place in neurology, sometimes overshadowed by Alzheimer’s and sometimes mistaken for it.
How Amyloid Ends Up in Blood Vessel Walls
The brain constantly produces amyloid beta as a byproduct of normal cell activity. Under healthy conditions, the protein is cleared out through perivascular drainage pathways, essentially channels that run along the walls of small arteries and carry waste fluid away from brain tissue. As people age, and especially if they carry certain genetic risk factors, those drainage pathways stiffen and slow down. The result is that amyloid beta that would normally be flushed away instead gets trapped in and around vessel walls.
Research in both human tissue and mouse models confirms this picture. In human brains with CAA, the distribution of amyloid deposits along capillaries and arteries closely matches the anatomy of the perivascular drainage system, strongly suggesting the protein gets stuck in transit rather than arriving from the bloodstream.
1PubMed Central. Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy Work in Alzheimer’s-model mice showed that drainage was already impaired in middle age and got progressively worse as the animals grew older and developed more vascular amyloid, indicating that CAA does not just result from poor clearance but actively worsens it, creating a self-reinforcing cycle.2PubMed Central. Cerebral amyloid angiopathy aggravates perivascular clearance impairment in an Alzheimer’s disease mouse model
Two forms of amyloid beta matter here. The shorter form, amyloid beta-40, tends to dominate in vessel walls, while the longer form, amyloid beta-42, is more concentrated in the brain plaques associated with Alzheimer’s disease. In CAA-affected vessels, amyloid beta-42 clusters on the outer edge of the vessel wall while amyloid beta-40 is distributed more broadly through it.3PubMed Central. High-definition characterization of cerebral β-amyloid angiopathy in Alzheimer’s disease This distinction is part of why CAA and Alzheimer’s can behave so differently even though the same family of proteins is involved.
What Happens to the Blood Vessels
As amyloid deposits thicken, they physically disrupt the vessel wall. The smooth muscle cells that normally give small arteries their tone and ability to regulate blood flow become disorganized and eventually die off. In a transgenic mouse model, researchers observed that these cells lost their orderly arrangement before they started dying, and that even structurally intact but disorganized cells failed to respond normally when prompted to dilate or constrict.4PubMed Central. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy This matters because the brain relies on moment-to-moment blood flow adjustments to match oxygen supply with demand. When that regulatory system breaks down, brain tissue can be chronically undersupplied even without an obvious bleed.
At more advanced stages, the structural breakdown goes further. Enzymes called matrix metalloproteinases, which normally help remodel tissue, become overactive around heavily affected vessels. In human CAA tissue, one of these enzymes (MMP-9) was found at significantly elevated levels in vessels with advanced amyloid deposits, and the areas where MMP-9 was most concentrated were the same areas that showed signs of prior bleeding.5PubMed Central. Matrix Metalloproteinase 9 mediated intracerebral hemorrhage induced by Cerebral amyloid angiopathy Another related enzyme, MMP-2, was found not only near acute bleeds but also in amyloid-damaged vessels far from any active hemorrhage, suggesting it contributes to an ongoing weakening process throughout the vascular network.6PubMed Central. MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke The cumulative result is progressive loss of vascular integrity: vessels that can no longer regulate flow, can no longer maintain a proper barrier between blood and brain tissue, and eventually rupture.7PubMed Central. Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit
Bleeding in the Brain and Its Patterns
The most dramatic consequence of CAA is intracerebral hemorrhage, specifically in the lobar regions of the brain (the outer areas of the cerebral hemispheres, as opposed to the deep structures where high-blood-pressure-related bleeds tend to occur). Recurrent lobar hemorrhage in an older adult is one of the strongest clinical clues that CAA is the underlying cause.8PubMed Central. Recurrence of Lobar Hemorrhage: A Red Flag for Cerebral Amyloid Angiopathy-related Inflammation? These bleeds can be large and symptomatic, or they can be tiny microbleeds visible only on sensitive brain imaging.
A distinctive feature of CAA-related hemorrhage is temporal clustering. In a study of nearly 700 patients, those with probable CAA had a five-fold higher risk of a second bleed in the first three months after an initial hemorrhage compared to the period from months four through twelve. Patients without CAA showed no such spike in early recurrence.9PubMed Central. Temporal and Spatial Clustering of Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy This clustering has real implications for how aggressively patients are monitored after a first event and whether blood-thinning drugs should be resumed.
Cortical Superficial Siderosis and Warning Episodes
Not all CAA-related bleeding is deep inside the brain. A characteristic finding on MRI is cortical superficial siderosis, which represents old blood-breakdown products deposited along the surface folds of the brain. In one study, about 40% of patients with probable CAA had this finding, compared to roughly 15% of patients with a single lobar bleed and under 5% of those with deep brain hemorrhage.10PubMed. Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy When siderosis is widespread (disseminated rather than focal), it carries a substantially higher risk of future major hemorrhage. A meta-analysis found that disseminated siderosis roughly quadrupled the risk of future bleeding, making it the single most important MRI-based predictor of hemorrhage in CAA patients.11PubMed Central. Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: A meta-analysis
Siderosis is also linked to a symptom that often baffles both patients and clinicians: transient focal neurologic episodes. These are brief spells of weakness, numbness, tingling, visual disturbance, or speech difficulty that can look identical to mini-strokes. About 15% of CAA patients in one multicenter cohort experienced them, with positive symptoms (spreading tingling, visual sparkles, limb jerking) and negative symptoms (sudden weakness or speech loss) occurring in roughly equal proportion.12PubMed. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis The danger is that a clinician who interprets these as ordinary mini-strokes might prescribe blood thinners, which is exactly the wrong treatment for someone whose blood vessels are already fragile from amyloid damage. The same study found that half of patients who had these episodes went on to have a symptomatic lobar hemorrhage over a median follow-up of 14 months, underlining the urgency of correct diagnosis.13PubMed. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis The underlying mechanism is likely cortical spreading depolarization triggered by superficial bleeding rather than a clot blocking an artery.14PubMed Central. Cerebral Amyloid Angiopathy-Related Transient Focal Neurologic Episodes
Cognitive Decline Without a Major Bleed
CAA does not need to cause a visible hemorrhage to damage cognition. Imaging and autopsy studies consistently show that ischemic injuries, tiny areas of tissue death from inadequate blood flow, are common in CAA even without large bleeds. These include white-matter damage (visible as bright spots on MRI) and cortical microinfarcts, pinpoint areas of dead tissue scattered across the brain’s surface.15PubMed Central. Ischemic brain injury in cerebral amyloid angiopathy In one cohort, patients who had these microinfarcts on MRI showed poorer executive function and slower processing speed compared to CAA patients without them, and their cumulative rate of developing dementia was higher.16PubMed Central. Cerebral Cortical Microinfarcts on Magnetic Resonance Imaging and Their Association With Cognition in Cerebral Amyloid Angiopathy Pathology studies in demented individuals with severe CAA confirm that frequent old microinfarcts contribute a vascular component to cognitive impairment.17PubMed Central. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy
This means that a person with CAA can experience a slow, progressive decline in thinking and memory driven by widespread small-vessel damage rather than by the amyloid plaques of Alzheimer’s disease. In practice, the two processes often overlap in the same brain, which makes disentangling what is causing what a persistent challenge for clinicians.
Inflammatory CAA
A distinct and often underrecognized variant is CAA-related inflammation. In this form, the immune system mounts a response against the amyloid in the vessel walls, causing swelling, white-matter changes, and a clinical picture that can include rapid cognitive decline, confusion, behavioral changes, headaches, and seizures.18PubMed Central. Inflammatory Cerebral Amyloid Angiopathy: A Broad Clinical Spectrum Two pathological subtypes exist: one dominated by inflammation around the vessels and another with more aggressive inflammation that penetrates the vessel wall itself.
The good news is that unlike most forms of CAA, the inflammatory variant often responds to immunosuppressive treatment, typically steroids and sometimes additional immune-suppressing drugs.19PubMed Central. Cerebral amyloid angiopathy-related inflammation: current status and future implications Recognizing it matters because the presentation can mimic a brain tumor, encephalitis, or rapidly progressive dementia. A set of clinical and radiological criteria for diagnosing it without a brain biopsy achieved a sensitivity and specificity of about 82% and 97%, respectively, for the “probable” category, which has made it easier to identify in practice.20JAMA Neurology. Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related Inflammation
How CAA Is Diagnosed
Definitive CAA diagnosis requires looking at brain tissue under a microscope, either at autopsy or from a biopsy. For living patients, clinicians rely on a set of criteria called the Boston criteria, which were recently updated to version 2.0. The new version requires that a patient aged 50 or older have at least two strictly lobar hemorrhagic lesions (bleeds, microbleeds, or foci of siderosis) on MRI, or one such lesion plus certain white-matter features such as enlarged perivascular spaces in a specific brain region or a characteristic “multispot” pattern of white-matter bright spots.21PubMed. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study
The update was a meaningful improvement. When tested against autopsy-confirmed diagnoses, version 2.0 picked up about 75% of true CAA cases while correctly ruling it out 95% of the time, compared to the original criteria’s sensitivity of roughly 65%.22PubMed. Validation of the Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy in Patients Presenting With Intracerebral Hemorrhage That jump in sensitivity matters because many patients with CAA were previously being missed.
The type of MRI sequence used also makes a difference. Susceptibility-weighted imaging detects roughly 1.6 times as many microbleeds as older gradient-echo sequences, with the advantage being even larger at higher magnetic field strengths.23PubMed Central. Comparing Susceptibility-Weighted Imaging and T2* Gradient-Recalled Echo for Cerebral Microbleeds Detection: A Systematic Review and Meta-Analysis Since the Boston criteria hinge on counting hemorrhagic lesions, a more sensitive scan can push a patient from “possible” to “probable” CAA.
Emerging Biomarkers and PET Imaging
Beyond standard MRI, researchers are working to distinguish CAA from Alzheimer’s disease using biomarkers measured in spinal fluid and blood, as well as amyloid PET scans. In spinal fluid, both amyloid beta-40 and amyloid beta-42 levels are lower in CAA patients than in healthy controls, with amyloid beta-40 in particular helping to separate CAA from Alzheimer’s. Meanwhile, tau protein levels in spinal fluid are lower in CAA than in Alzheimer’s, which makes sense given that tau tangles are more central to Alzheimer’s pathology.24PubMed Central. CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis Blood-based amyloid markers, however, have not yet shown the ability to reliably distinguish CAA patients from healthy individuals.
Amyloid PET scans, which light up wherever amyloid is deposited in the brain, reveal a subtle but informative difference between CAA and Alzheimer’s. Both conditions show widespread amyloid signal, but CAA tends to produce a relatively higher proportion of signal in the occipital (back-of-the-brain) region compared to global uptake, while Alzheimer’s shows higher uptake in frontal and temporal areas.25European Stroke Journal. Cerebral amyloid angiopathy and amyloid load distribution detected on amyloid–positron emission tomography: A systematic review and meta-analysis A PET study using the tracer florbetapir confirmed that overall amyloid retention was lower in CAA than in Alzheimer’s patients, with a trend toward a higher occipital-to-global ratio in CAA.26PubMed Central. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer’s Disease: A PET Study Adding tau PET to the mix may sharpen the distinction further, since CAA patients tend to have much lower tau signal than Alzheimer’s patients in key brain regions.27Journal of Stroke. Differentiating Cerebral Amyloid Angiopathy From Alzheimer’s Disease Using Dual Amyloid and Tau Positron Emission Tomography
The Genetics Behind It
The most well-studied genetic factor in sporadic CAA is the apolipoprotein E gene, the same gene famously linked to Alzheimer’s risk. Having two copies of the APOE-ε4 variant carries the strongest association with amyloid buildup in blood vessels. In one large autopsy series, nearly all APOE-ε4/ε4 brains showed the highest grade of vascular amyloid in the occipital lobe, compared to about 43% of those with one ε4 copy and only 19% of those with the common ε3/ε3 genotype.28PubMed Central. APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature
The APOE-ε2 variant presents a paradox. It is generally considered protective against Alzheimer’s disease, yet brains carrying one copy of ε2 showed more vascular amyloid than ε3/ε3 brains in the same study.29PubMed Central. APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature Furthermore, ε2 has been specifically linked to a higher risk of actual hemorrhage in CAA, possibly because the form of apolipoprotein E it produces alters the structural integrity of amyloid-laden vessel walls. One study found that antiplatelet or anticoagulant use, hypertension, and even minor head trauma were most likely to trigger a brain bleed in CAA patients who were also ε2 carriers.30PubMed. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon2 with putative clinical risk factors. So ε4 promotes amyloid deposition while ε2 seems to promote vessel rupture once the amyloid is already there.
Rare hereditary forms of CAA also exist, caused by mutations in the gene for the amyloid precursor protein. The best-known is the Dutch type, which causes strokes and dementia typically beginning in middle age. These familial forms are inherited in an autosomal dominant pattern, meaning a single copy of the mutated gene is enough to cause disease. Although each mutation produces a somewhat different clinical picture, they share features of earlier onset and more severe disease compared to the common sporadic form.31Cerebral Circulation – Cognition and Behavior. Main features of hereditary cerebral amyloid angiopathies: A systematic review
How CAA Relates to Alzheimer’s Disease
Because the same protein family drives both conditions, CAA and Alzheimer’s frequently share a brain. In a large autopsy database, the severity of CAA tracked closely with the severity of Alzheimer’s pathology, with roughly 45% of brains with the most severe Alzheimer’s plaque burden showing moderate-to-severe CAA.32PubMed Central. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways But the overlap is not absolute. About a fifth of brains with heavy Alzheimer’s plaque burden had no CAA at all, and about a fifth of brains with CAA had no significant Alzheimer’s plaques.33PubMed Central. Cerebral amyloid angiopathy and its co-occurrence with Alzheimer’s disease and other cerebrovascular neuropathologic changes CAA is clearly its own entity, not just a sideshow of Alzheimer’s.
This overlap has become clinically urgent with the arrival of anti-amyloid immunotherapies for Alzheimer’s disease. These drugs work by clearing amyloid from the brain, but one of their recognized side effects, known as amyloid-related imaging abnormalities, involves swelling and small bleeds that look strikingly similar to what CAA already causes. Patients with pre-existing CAA appear to be at higher risk for these complications, which has forced treatment teams to screen more carefully for CAA markers before starting therapy.
The Blood-Thinner Dilemma
One of the most difficult clinical decisions in CAA involves patients who also have atrial fibrillation, a common heart rhythm disorder that raises the risk of stroke from blood clots. The standard treatment for atrial fibrillation is anticoagulation, but in someone with CAA, thinning the blood may tip the balance toward a catastrophic brain hemorrhage. CAA is one of the main risk factors for spontaneous brain bleeding, and that risk climbs when blood thinners are added.34PubMed Central. When Atrial Fibrillation Meets Cerebral Amyloid Angiopathy: Current Evidence and Strategies There is no clear consensus on how to handle this tension; clinicians must weigh each patient’s individual balance of clot risk versus bleed risk.35PubMed Central. Management of cerebral amyloid angiopathy and atrial fibrillation: We are still far from precision medicine
One emerging alternative is left atrial appendage closure, a procedure that physically seals off the small pouch in the heart where most dangerous clots form, reducing the need for long-term anticoagulation. A small cohort study of CAA patients who underwent this procedure found that it was well tolerated, with no hemorrhages or ischemic strokes in the 30 days after implantation and only one ischemic stroke over an average 25-month follow-up.36PubMed Central. Left Atrial Appendage Closure for Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation: the LAA-CAA Cohort The numbers are too small to call it proven, but the early results suggest it could become a practical solution for patients caught between two dangerous conditions.
Why CAA Took So Long to Be Recognized
Amyloid deposits in brain blood vessels were first described pathologically nearly a century ago, but the connection between those deposits and clinical brain hemorrhage was not established until the 1970s and 1980s.37JAMA Neurology. Cerebral Amyloid Angiopathy and Lobar Intracerebral Hemorrhage For decades, unexplained lobar bleeds in elderly patients were often attributed to high blood pressure or simply labeled “cryptogenic.” The development of MRI sequences sensitive to old blood products, particularly susceptibility-weighted imaging, transformed the field by revealing that many of these patients had dozens or even hundreds of tiny microbleeds in a lobar distribution, a pattern that screams CAA once you know to look for it.38PubMed Central. Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging Formal diagnostic criteria followed, and the 2022 update to the Boston criteria represents the current state of the art. Even so, awareness remains uneven: many clinicians outside specialist stroke and dementia centers still underappreciate CAA’s role in cognitive decline, particularly in patients who have never had an obvious hemorrhage.